SCHEMBL5481754

SCHEMBL5481754

CN(C)c1ccc(C2(c3ccc(N(C)C)cc3)C(=O)Nc3oc(Cl)cc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.40
ALDH1A1 P00352 5/20 0.39
HSD17B10 Q99714 3/20 0.39
HPGD P15428 2/20 0.39
CYP3A4 P08684 1/20 0.39
HIF1A Q16665 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 2/20 0.33
NOTUM Q6P988 1/20 0.33
MAPT P10636 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
PGR P06401 1/20 0.31
FLI1 Q01543 1/20 0.31
EWSR1 Q01844 1/20 0.31
CNR1 P21554 1/20 0.31
HTT P42858 1/20 0.31
GPR35 Q9HC97 1/20 0.31
GPR55 Q9Y2T6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482166 0.81 CHRM2 (0.49) HTR6ALDH1A1HSD17B10CYP3A4TDP1
SCHEMBL5483571 0.76 MAPT (0.56) ALDH1A1HSD17B10HPGDCYP3A4TDP1
SCHEMBL5478018 0.75 ALDH1A1 (0.38) HTR6ALDH1A1HSD17B10HPGDCYP3A4
SCHEMBL5478006 0.72 HTR6 (0.40) HTR6ALDH1A1HSD17B10HPGDCYP3A4
SCHEMBL5481659 0.67 ALDH1A1 (0.35) HTR6ALDH1A1HSD17B10HPGDCYP3A4
SCHEMBL13145365 0.64 CHRM2 (0.78) ALDH1A1HPGDCYP3A4TDP1MEN1
SCHEMBL5483644 0.64 ALDH1A1 (0.33) HTR6ALDH1A1HSD17B10HPGDCYP3A4
SCHEMBL5485875 0.63 CNR1 (0.41) ALDH1A1HSD17B10HPGDCYP3A4HIF1A
SCHEMBL5478439 0.62 ALDH1A1 (0.37) HTR6ALDH1A1HSD17B10HPGDTDP1
SCHEMBL11299095 0.59 TDP1 (0.72) HTR6ALDH1A1HSD17B10HPGDCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 HTR6 639/4885ALDH1A1 2650/4885HSD17B10 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.